GEROTHERAPEUTIX
LIVE

Serial Number

99753230

Owner

SENOTHERAPEUTIX, Inc.

Attorney

Jared L. DuJack

Filing Date

Apr 9, 2026

Add to watchlist:

No watchlists yet
View on USPTO

GEROTHERAPEUTIX Trademark

Serial Number: 99753230

GEROTHERAPEUTIX is a trademark filed by SENOTHERAPEUTIX, Inc. on April 9, 2026. The trademark is classified under Class 3 (Cosmetics & Cleaning). The application is currently pending registration.

Owner Contact Info

SENOTHERAPEUTIX, Inc. (2 trademarks)

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

April 9, 2026

Registration Date

Not Registered

Goods & Services

Anti-aging cream; Non-medicated anti-aging serum; Cosmetic anti-aging products, namely, anti-aging creams, serums, moisturizers, tonics, and cleansers; Cosmetic preparations; Cosmetic creams for skin care; Cosmetic preparations for skin care; Pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Gene therapy-based pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Synthesized peptides for use in treating age-related diseases and cancer; Synthesized peptides for use in skin conditions; Synthesized peptides, namely anti-aging peptides; Synthesized peptides for use in prevention of radiation damage; Synthesized peptides for use in treatment of radiation damage; Synthesized peptides for use in prevention of radiation related diseases; Synthesized peptides for use in treatment of radiation related diseases; Synthesized peptides for use in treatment of obesity; Synthesized peptides for use in weight loss regimens, Synthesized peptides for use in treatment of obesity in combination with other drugs; Synthesized peptides, namely, peptides for use in cosmetics; Synthesized peptides, namely, anti-aging peptides for use in cosmetics; Development of pharmaceutical preparations and medicines; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Testing, inspection, research, and development of pharmaceutical preparations for age therapy and gene therapy; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Cosmetic research; Development of cosmetic preparations; Research and development of cosmetic preparations; Gene therapy research; Gene therapy research related to anti-aging; Gene therapy research related to cancer; Gene therapy related to prevention and treatment of radiation damage and radiation related diseases; Gene therapy related to treatment of obesity; Gene therapy related to weight loss regimens; Gene therapy related to treatment of obesity in combination with other drugs; Anti-aging research; Medical research services; Medical research services, namely, anti-aging services; Medical research services, namely, prevention and treatment of age-related disorders; Anti-aging therapy; Medical services, namely, anti-aging services; Medical testing services, namely, biologic age scoring; Medical testing services in the nature of statistical scoring to determine a biologic age score of a patient; Medical services; Medical services, namely, prevention and treatment of age-related disorders; Medical advisory services; Medical advisory services, namely, anti-aging services; Medical advisory services, namely, prevention and treatment of age-related disorders; Medical testing services; Medical testing services, namely, anti-aging services; Medical testing services, namely, prevention and treatment of age-related disorders; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical testing services, namely, biopsy services; Medical testing services, namely, biopsy services related to biologic age; Medical testing services, namely, biopsy services related to biological age scoring; Medical testing services, namely, biopsy services related to determining a number or percentage of senescent cells; Laboratory services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Laboratory services related to biologic age, namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Laboratory services related to biological age scoring, namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, laboratory services related to determining a number or percentage of senescent cells; Non-invasive medical testing; Non-invasive medical testing related to biologic age; Non-invasive medical testing related to biological age scoring; Non-invasive medical testing related to determining a number or percentage of senescent cells; Medical care, namely, prevention of radiation damage; Medical care, namely, treatment of radiation damage; Medical care, namely, prevention of radiation related diseases; Medical care, namely treatment of radiation related diseases; Medical care, namely, treatment of obesity; Providing weight loss program services in the nature of weight loss regimens; Medical care, namely, treatment of obesity in combination with other drugs; Consulting services in the fields of medical care pertaining to anti-aging and cosmetics; Medical skin care services, namely, biologic age scoring for use in cosmetics; Medical care, namely, statistical scoring to determine a biologic age score of an individual

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 19, 2026 GNRN
NON-FINAL ACTION E-MAILED
Aug 19, 2026 GNRT
NON-FINAL ACTION WRITTEN
Aug 19, 2026 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 18, 2026 GNRN
NON-FINAL ACTION E-MAILED
Aug 18, 2026 GNRT
NON-FINAL ACTION WRITTEN
Aug 18, 2026 CNRT
ASSIGNED TO EXAMINER
Aug 18, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 30, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Apr 9, 2026 MAFR
NEW APPLICATION ENTERED
Apr 9, 2026 NWAP